RDPAC is a committee of the China Association of Enterprises with Foreign Investment (CAEFI). It is a non-profit organization made up of 45 member companies with pharmaceutical R&D capabilities.

OVERVIEW

Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 45 member companies with pharmaceutical R&D capability.

As of June 2020, RDPAC member companies have established 47 manufacturing facilities and 25 R&D centers in mainland China. From July 2015 to June 2020, RDPAC member companies have introduced more than 206 innovative drugs to China market.

VISION


HEALTHIER CHINA THROUGH INNOVATION


To be a valued partner in delivering the “Healthy China” goal to improve the health and quality of life of people in China:
•      Provide high-quality/ innovative healthcare products and services in a socially responsible and commercially viable manner;
•      Commit to securing patients timely access to innovative & high quality drugs;
•      Achieve the highest standard of integrity for ethical research and business practice;
•      Contribute to the growth of the biopharmaceutical sector in China;
•      Support the development of a sustainable healthcare system in China.

RDPAC Executive Committee(2022-2023)

RDPAC CODE

A major requisite for innovation is integrity, which is also the foundation of reputation. Without ethical decision-making, there is no true innovation.


As the first pharmaceutical industry organization in China to attach great importance to compliance, and as a member and an active player of the global pharmaceutical industry association network, RDPAC has continuously strived to reflect the latest standards of international pharmaceutical industry associations, using the Code of Practice of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) as its foundation in doing so. At the same time, RDPAC has kept abreast of the latest requirements of Chinese laws, regulations and policies, and the cutting-edge developments in business practices and compliance controls in China's pharmaceutical industry, providing member companies with the latest and highest standards of compliance based on best practice. Adherence to the RDPAC Code of Practice has also been made a precondition for companies to join RDPAC. Furthermore, RDPAC is supportive of the member companies’ intention to develop and implement their more stringent in-house codes of practice on this basis.


READ MORE

DOWNLOAD